{"id":"https://openalex.org/W2919158317","doi":"https://doi.org/10.1097/cmr.0000000000000585","title":"Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients","display_name":"Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients","alternate_titles":[],"publication_year":2019,"publication_date":"2019-03-03","ids":{"openalex":"https://openalex.org/W2919158317","doi":"https://doi.org/10.1097/cmr.0000000000000585","mag":"2919158317","pmid":"https://pubmed.ncbi.nlm.nih.gov/30817442"},"language":"en","primary_location":{"id":"doi:10.1097/cmr.0000000000000585","doi":"https://doi.org/10.1097/cmr.0000000000000585","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000585","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2919158317"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080101109","display_name":"Marie-L\u00e9a Gauci","orcid":"https://orcid.org/0000-0003-3081-9810","observed_orcids":["https://orcid.org/0000-0003-3081-9810"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Marie-L\u00e9a Gauci","raw_affiliation_strings":["AP-HP Department of Dermatology, INSERM U976","fax:+33 142 494 465"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Dermatology, INSERM U976","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159"]},{"raw_affiliation_string":"fax:+33 142 494 465","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076367607","display_name":"Philippe Boudou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Philippe Boudou","raw_affiliation_strings":["AP-HP Derpartment of Hormonology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Derpartment of Hormonology","institution_ids":["https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068776324","display_name":"Pierre-Alexandre Squara","orcid":"https://orcid.org/0000-0001-5998-8285","observed_orcids":["https://orcid.org/0000-0001-5998-8285"]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pierre-Alexandre Squara","raw_affiliation_strings":["AP-HP Department of Statistics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Statistics","institution_ids":["https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077749760","display_name":"Julie Delyon","orcid":"https://orcid.org/0000-0002-4557-3377","observed_orcids":["https://orcid.org/0000-0002-4557-3377"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Julie Delyon","raw_affiliation_strings":["AP-HP Department of Dermatology, INSERM U976"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Dermatology, INSERM U976","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065819179","display_name":"Clara Allayous","orcid":"https://orcid.org/0000-0002-1762-152X","observed_orcids":["https://orcid.org/0000-0002-1762-152X"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Clara Allayous","raw_affiliation_strings":["AP-HP Department of Dermatology, INSERM U976"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Dermatology, INSERM U976","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007042449","display_name":"Samia Mourah","orcid":"https://orcid.org/0000-0002-9283-1068","observed_orcids":["https://orcid.org/0000-0002-9283-1068"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Samia Mourah","raw_affiliation_strings":["AP-HP Pharmacogenomic Laboratory, INSERM U976, Saint-Louis Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Pharmacogenomic Laboratory, INSERM U976, Saint-Louis Hospital","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159","https://openalex.org/I4210144610"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026054699","display_name":"Matthieu Resche\u2010Rigon","orcid":"https://orcid.org/0000-0003-2220-5085","observed_orcids":["https://orcid.org/0000-0003-2220-5085"]},"institutions":[{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Matthieu Resche-Rigon","raw_affiliation_strings":["AP-HP Department of Statistics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Statistics","institution_ids":["https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025478490","display_name":"C\u00e9l\u00e8ste Lebb\u00e9","orcid":"https://orcid.org/0000-0002-5854-7290","observed_orcids":["https://orcid.org/0000-0002-5854-7290"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"C\u00e9leste Lebb\u00e9","raw_affiliation_strings":["AP-HP Department of Dermatology, INSERM U976"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Dermatology, INSERM U976","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089551729","display_name":"Barouyr Baroudjian","orcid":"https://orcid.org/0000-0003-4703-8340","observed_orcids":["https://orcid.org/0000-0003-4703-8340","https://orcid.org/0000-0001-8234-6766"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Barouyr Baroudjian","raw_affiliation_strings":["AP-HP Department of Dermatology, INSERM U976"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Dermatology, INSERM U976","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047821902","display_name":"Jean\u2013Fran\u00e7ois Gautier","orcid":"https://orcid.org/0000-0001-6458-2001","observed_orcids":["https://orcid.org/0000-0001-6458-2001"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210092322","display_name":"Centre de Recherche des Cordeliers","ror":"https://ror.org/00dmms154","country_code":"FR","type":"facility","lineage":["https://openalex.org/I154526488","https://openalex.org/I204730241","https://openalex.org/I39804081","https://openalex.org/I4210092322"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210119095","display_name":"H\u00f4pital Lariboisi\u00e8re","ror":"https://ror.org/02mqtne57","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210119095"]},{"id":"https://openalex.org/I4387154366","display_name":"Universit\u00e9 Paris Diderot","ror":"https://ror.org/02n7qrg46","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387154366"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jean-Fran\u00e7ois Gautier","raw_affiliation_strings":["AP-HP Department of Diabetology, INSERM U1138, Lariboisi\u00e9re Hospital, Universit\u00e9 Paris Diderot - Paris VII, Sorbonne Paris Cit\u00e9, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AP-HP Department of Diabetology, INSERM U1138, Lariboisi\u00e9re Hospital, Universit\u00e9 Paris Diderot - Paris VII, Sorbonne Paris Cit\u00e9, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210092322","https://openalex.org/I4210097159","https://openalex.org/I4210119095","https://openalex.org/I4387154366"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5080101109"],"corresponding_institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210097159"],"apc_list":null,"apc_paid":null,"fwci":0.7238,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.69492247,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":96},"biblio":{"volume":"29","issue":"3","first_page":"328","last_page":"332"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12433","display_name":"Skin Diseases and Diabetes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11171","display_name":"Diabetes and associated disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8960000276565552},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8949999809265137},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.7990000247955322},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9559999704360962},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8240000009536743},{"id":"https://openalex.org/keywords/glucose-metabolism","display_name":"glucose metabolism","score":0.7379999756813049},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.5289999842643738},{"id":"https://openalex.org/keywords/glucocorticoids","display_name":"glucocorticoids","score":0.7369999885559082},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.640999972820282},{"id":"https://openalex.org/keywords/chronic-inflammation","display_name":"chronic inflammation","score":0.5609999895095825},{"id":"https://openalex.org/keywords/adverse-effects-of-immunotherapy","display_name":"adverse effects of immunotherapy","score":0.6539999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8920513391494751},{"id":"https://openalex.org/C119060515","wikidata":"https://www.wikidata.org/wiki/Q1916617","display_name":"Interquartile range","level":2,"score":0.875908374786377},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6570484042167664},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.6488456130027771},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4970572292804718},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4850127398967743},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4834512174129486},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.44659772515296936},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.4424690008163452},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.42100054025650024},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.38357412815093994},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.36859434843063354},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.14050915837287903}],"mesh":[{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D002318","descriptor_name":"Cardiovascular Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/cmr.0000000000000585","doi":"https://doi.org/10.1097/cmr.0000000000000585","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000585","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},{"id":"pmid:30817442","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30817442","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1985362580","https://openalex.org/W1994174603","https://openalex.org/W2014663082","https://openalex.org/W2022119612","https://openalex.org/W2033459138","https://openalex.org/W2107598346","https://openalex.org/W2110590807","https://openalex.org/W2110630581","https://openalex.org/W2126483958","https://openalex.org/W2128035403","https://openalex.org/W2128758225","https://openalex.org/W2143902379","https://openalex.org/W2152897456","https://openalex.org/W2165334726","https://openalex.org/W2166662937","https://openalex.org/W2296110227","https://openalex.org/W2602518814","https://openalex.org/W2805183535","https://openalex.org/W2895572113"],"related_works":["https://openalex.org/W2805183535","https://openalex.org/W4297504246","https://openalex.org/W2951530707","https://openalex.org/W4283008459","https://openalex.org/W2954626501","https://openalex.org/W2768097739","https://openalex.org/W2994821680","https://openalex.org/W2019426437","https://openalex.org/W3022460159","https://openalex.org/W3022764227"],"abstract_inverted_index":{"Immunotherapy":[0],"greatly":[1],"improves":[2],"clinical":[3],"outcomes":[4],"in":[5,48,61,88,102,119,164,186,239],"treated":[6,89,104],"patients":[7,103,134,142,190],"with":[8,46,105,225,250],"cancer.":[9],"However,":[10],"the":[11,27,49,62,136,187,226],"long-lasting":[12],"immune":[13],"response":[14],"and":[15,56,114,151,220],"long":[16],"duration":[17],"of":[18,51,189],"therapy":[19,80],"could":[20,81],"induce":[21],"long-term":[22],"adverse":[23],"effects":[24],"owing":[25],"to":[26,83,92,130,175,208],"chronic":[28],"inflammation":[29],"induced.":[30],"Type":[31],"2":[32,85],"diabetes":[33,86],"is":[34,44],"now":[35],"recognized":[36],"as":[37,217,257],"an":[38,120,162],"inflammatory":[39,63],"disease.":[40],"In":[41],"addition,":[42],"immunotherapy":[43],"concerned":[45],"increase":[47,163],"production":[50],"tumor":[52],"necrosis":[53],"factor-\u03b1,":[54],"interleukin-2,":[55],"interferon-\u03b3,":[57],"which":[58],"are":[59],"involved":[60],"process.":[64],"Based":[65],"on":[66],"these":[67],"observations,":[68],"we":[69,96],"hypothesized":[70],"that":[71,248],"anti-programmed":[72],"cell":[73],"death-1":[74],"(anti-PD-1)":[75],"and/or":[76,107],"anticytotoxic":[77,108],"T-lymphocyte-associated":[78,109],"protein-4":[79,110],"contribute":[82],"type":[84],"genesis":[87],"patients.":[90],"Therefore,":[91],"evaluate":[93],"this":[94],"hypothesis,":[95],"studied":[97],"HbA1c":[98,145,165,199,227,235,261],"levels":[99,166,200,236],"during":[100,147],"follow-up":[101,149,156],"anti-PD-1":[106,251],"therapy.":[111],"A":[112],"prospective":[113],"observational":[115],"study":[116,246],"was":[117,157,184,237],"performed":[118],"oncodermatology":[121],"department":[122],"(Saint-Louis":[123],"Hospital,":[124],"Paris,":[125],"France)":[126],"from":[127,167,202],"March":[128],"2015":[129],"February":[131],"2017.":[132],"Sixty-two":[133],"meeting":[135],"inclusion":[137],"criteria":[138],"were":[139,152,222],"enrolled.":[140],"Forty-three":[141],"had":[143],"paired":[144],"measurements":[146],"their":[148,197],"period":[150],"analyzed.":[153],"The":[154],"median":[155,198],"3":[158],"months.":[159,244],"We":[160],"noted":[161],"5.3%":[168,203],"[interquartile":[169],"range":[170],"(IQR):":[171],"5.1-5.5;":[172,205],"range:":[173,179,206,212],"4.5-6.2)":[174],"5.45%":[176],"(IQR:":[177,204,210],"5.2-5.7;":[178,211],"4.7-6.2;":[180],"P=0.037).":[181],"This":[182,245],"observation":[183],"confirmed":[185],"subgroup":[188],"who":[191],"did":[192],"not":[193,223],"receive":[194],"concomitant":[195],"glucocorticoids;":[196],"increased":[201],"4.7-6.2)":[207],"5.5%":[209],"4.7-6.3;":[213],"P=0.025).":[214],"Variables":[215],"such":[216],"age,":[218],"BMI,":[219],"sex":[221],"associated":[224],"level":[228],"increase,":[229],"but":[230],"a":[231],"tendency":[232],"toward":[233],"rising":[234],"observed":[238],"treatments":[240],"longer":[241],"than":[242],"12":[243],"demonstrates":[247],"treatment":[249],"antibodies":[252],"may":[253],"impair":[254],"glucose":[255],"metabolism,":[256],"measured":[258],"by":[259],"increasing":[260],"levels.":[262]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2919158317","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2019-03-11T00:00:00"}
